Technical Analysis for SGEN - Seattle Genetics, Inc.

Grade Last Price % Change Price Change
grade C 55.23 -0.29% -0.16
SGEN closed down 0.29 percent on Tuesday, May 22, 2018, on 51 percent of normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical SGEN trend table...

Date Alert Name Type % Chg
May 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
May 22 Cup with Handle Other 0.00%
May 22 Down 3 Days in a Row Weakness 0.00%
May 22 Down 4 Days in a Row Weakness 0.00%
May 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.29%
May 21 Cup with Handle Other -0.29%
May 21 Down 3 Days in a Row Weakness -0.29%
May 18 Cup with Handle Other -2.71%
May 18 Overbought Stochastic Strength -2.71%
May 17 Bearish Engulfing Bearish -3.66%

Older signals for SGEN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Food and Drug Administration for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens; and for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The company's ADCETRIS is in Phase III trial for patients with Hodgkin lymphoma at high risk of relapse following ASCT; Phase II retreatment trial for patients with Hodgkin lymphoma or sALCL; Phase II trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas; Phase II CD30-screening and treatment trial for patients with CD30-positive non-lymphoma malignancies; Phase I safety trial in combination with Adriamycin, vinblastine, bleomycin, and dacarbazine, or in combination with AVD for front-line treatment of patients with Hodgkin lymphoma; and Phase I safety trial for the treatment of patients with mature T-cell lymphomas, including sALCL. Its product pipeline also comprises SGN-75, which completed Phase I trial for relapsed or refractory non-Hodgkin lymphoma and renal cell carcinoma; ASG-5ME that is in Phase I trial for treating metastatic pancreatic cancer and castration-resistant prostate cancer; ASG-22ME, which is in Phase I trial for treatment of Nectin-4 -positive solid tumors; and SGN-CD19A for CD19-positive hematologic malignancies. The company has a strategic collaboration with Oxford BioTherapeutics Ltd. to jointly discover antibody-drug conjugates (ADC) for the treatment of cancer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.
Is SGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 67.97
52 Week Low 45.31
Average Volume 934,867
200-Day Moving Average 54.6168
50-Day Moving Average 53.218
20-Day Moving Average 54.383
10-Day Moving Average 56.612
Average True Range 1.8405
ADX 29.19
+DI 28.01
-DI 17.22
Chandelier Exit (Long, 3 ATRs ) 53.5735
Chandelier Exit (Short, 3 ATRs ) 53.2715
Upper Bollinger Band 59.9547
Lower Bollinger Band 48.8113
Percent B (%b) 0.58
BandWidth 20.490594
MACD Line 1.237
MACD Signal Line 1.1664
MACD Histogram 0.0706
Fundamentals Value
Market Cap 7.9 Billion
Num Shares 143 Million
EPS -1.43
Price-to-Earnings (P/E) Ratio -38.62
Price-to-Sales 20.40
Price-to-Book 15.26
PEG Ratio -0.08
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 56.97
Resistance 3 (R3) 57.09 56.63 56.68
Resistance 2 (R2) 56.63 56.19 56.57 56.58
Resistance 1 (R1) 55.93 55.91 55.70 55.81 56.49
Pivot Point 55.47 55.47 55.36 55.41 55.47
Support 1 (S1) 54.77 55.03 54.54 54.65 53.97
Support 2 (S2) 54.31 54.75 54.25 53.88
Support 3 (S3) 53.61 54.31 53.78
Support 4 (S4) 53.49